The past 2-3 years in the Indian pharmaceutical industry has witnessed two distinct trends – one, wherein MNCs have explored the India shores through acquisitions and the second, where Indian companies have expanded their global footprints, built  front-end presence in the US/ European/ South Asian market via inorganic routes (mergers or acquisitions). And it is the latter trend, which is emerging to be stronger of the two.

The pharmaceutical sector leads the outbound deals in terms of value. Of the nearly USD 2.5 billion worth of M&A deals in 2006, approximately USD1.25 billion were outbound deals.

This is an extract from the Update Newsletter to our report "Pharmaceutical Outsourcing in Drug Discovery and Development: Contract Research Opportunity in India". The newsletters are sent complimentary with the report.

To purchase the report, click here.

Related Items:

1. Growing Demand for Biotechnology and India Opportunity
2. Pharma Cos hiving off R&D units
3. Integrated CRAMS Vendors
4. Challenges to overcome – Indian Bioinformatics Vendors
5. Partnering in CRAMS: From customers to partners…